Key result
Appropriate anticoagulation leaves many AF patients with up to ~2% annual residual stroke risk.
Why the study?
A significant proportion of patients with AF remain at high residual stroke risk despite receiving appropriate dose-adjusted anticoagulation.
A significant proportion of patients with AF remain at high residual stroke risk despite receiving appropriate dose-adjusted anticoagulation, necessitating exploration of further therapeutic options.
Residual stroke risk persists despite anticoagulation in AF; leaves open adjunctive strategies for prospective trials.
AF contributes to increased stroke risk via various mechanisms, including deranged blood constituents, vessel wall abnormalities and abnormal blood flow. This excess risk is frequently managed with anticoagulation therapy, aimed at preventing thromboembolic complications. Yet, a significant proportion of patients with AF remain at high residual stroke risk despite receiving appropriate dose-adjusted anticoagulation. This article explores the residual stroke risk in AF and potential therapeutic options for these patients.
No takes yet. Share an insight, caveat, or question.
Wern Yew Ding (2021) conducted a review in Atrial Fibrillation. Anticoagulation therapy was evaluated. A significant proportion of patients with atrial fibrillation remain at high residual stroke risk (1.11% to 2.40% per year) despite receiving appropriate dose-adjusted anticoagulation therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: